October 20, 2020
FOR IMMEDIATE RELEASE
Contact: Joanie Manzo
Director, OHC Marketing & Physician Services
513-751-2273 EXT. 10143
Unfortunately, many of these patients later experience a relapse. Even though the chemotherapy initially stopped the cancer’s growth, it now no longer responds to the chemotherapy. This is why doctors need new options to stop the cancer.
“At OHC, we offer promising new treatments for ovarian cancer through our clinical trials program. This includes a new clinical trial in which we are evaluating an immunotherapy drug in combination with chemotherapy to treat advanced ovarian cancer,” said OHC’s Dené C. Wrenn, MD, MS, gynecologic oncologist.
“The combination of an immunotherapy drug – in this case Keytruda – with chemotherapy is like a two-pronged attack,” Dr. Wrenn explained. “Keytruda helps the body’s immune system attack the cancer while the chemotherapy attacks the cancer directly. This combination has demonstrated an ability to stop the chemotherapy-resistant tumor from growing and spreading, offering patients an extended survival.”
OHC is the only cancer group in Greater Cincinnati to offer this ovarian cancer clinical trial.
The gynecologic cancer experts at OHC are helping women fight ovarian cancer by offering the latest treatments and promising new treatments through clinical trials. OHC is changing lives and offering a new sense of hope for women with all stages of ovarian cancer.Comments (0)